[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"point-of-care-testing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:point-of-care-testing":138},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,81,124,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100631652","the-pre-poct-non-conveyance-trial-prehospital-point-of-care-testing-to-support-non-conveyance-decisions-100631652",false,"NCT07503470","The Pre-POCT-Non-Conveyance Trial: Prehospital Point-of-Care Testing to Support Non-Conveyance Decisions","Prehospital Point-of-Care Testing to Support Decision-Making in Alternative and Non-Conveyance Pathways: A Matched Parallel Cluster-Randomised Trial. The Pre-POCT-Non-Conveyance Trial","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Emergency call or general practitioner-commissioned ambulance dispatch following telephone triage only, including video streaming triage, resulting in ambulance dispatch\n* Initial on-scene assessments performed by the ambulance crew\n* Patients initially considered for hospital conveyance based on clinical assessment\n* Following telemedical consultation with an Emergency Medical Dispatch Centre (EMDC) physician, deemed eligible for point-of-care blood testing (POCT)\n* Hemodynamically and clinically stable according to predefined operational stability criteria (including Glasgow Coma Scale, blood pressure, oxygen saturation, and heart rate), with final eligibility determined by the EMDC physician based on overall clinical assessment and the patient's baseline status\n\nExclusion Criteria:\n\n* Non-emergency calls (e.g., interfacility transport or scheduled patient transport)\n* General practitioner-commissioned ambulance dispatches where the patient has been physically assessed by a general practitioner or another physician before ambulance arrival\n* Immediate need for emergency transport to hospital as determined by clinical assessment\n* Persistent unstable vital signs outside predefined operational thresholds, except for known chronic baseline deviations (e.g., reduced oxygen saturation in patients with chronic obstructive pulmonary disease or chronic tachyarrhythmia in atrial fibrillation)\n* Inability to obtain venous or capillary blood samples\n* Prior participation in the study within 30 days (to ensure complete outcome follow-up)","ALL","18 Years",{"count":19,"type":20},1500,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate whether rapid blood tests performed in the ambulance can be implemented in routine prehospital assessment of adults who are initially considered for transport to hospital. Ambulance clinicians frequently assess adults who are transported to hospital but discharged shortly after arrival without requiring advanced diagnostic testing or treatment.\n\nIn this study, researchers will examine whether adding rapid point-of-care blood testing (POCT) at the scene supports ambulance clinicians and Emergency Medical Dispatch Centre (EMDC) physicians in making more informed decisions about hospital conveyance. POCT provides rapid measurements of biomarkers including infection markers, electrolytes, kidney function, blood counts, and total carbon dioxide, a proxy measure related to acid-base status.\n\nTen ambulance clusters will participate in a matched, cluster-randomized design. Half will provide standard care, and half will have access to POCT following consultation with an EMDC physician in patients who would otherwise be considered for hospital transport.\n\nThe main question is whether prehospital POCT can be performed, documented, and made available before the final conveyance decision in routine ambulance-based assessment. The study will also examine whether access to POCT is associated with a higher proportion of patients remaining at home rather than being transported to hospital.\n\nSafety outcomes will include hospital admission within 24 hours among non-conveyed patients, short-stay hospitalization, intensive care unit (ICU) admission, and 30-day mortality.\n\nThis study will evaluate the implementation of POCT-supported decision-making in prehospital care and explore whether it may increase non-conveyance without compromising patient safety.",[26,27,28],"Prehospital Emergency Medical Services","Prehospital Emergency Care","Point of Care Testing",[30,31,32,33,34],"emergency medical services","point of care testing","POCT","Non-conveyance","decision-making","RECRUITING","2026-05-29",{"date":38,"type":39},"2026-06-01","ACTUAL",{"date":41,"type":39},"2026-05-26",{"date":43,"type":20},"2027-12-31",{"name":45,"class":46},"Central Denmark Region","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100606069","clinical-performance-evaluation-of-magia-ivd-md-multiplex-testing-hivhbvhcvsyphilis-100606069","NCT07170748","Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV\u002FHBV\u002FHCV\u002FSyphilis)","Clinical Performance Evaluation of MagIA In-vitro Diagnostic Medical Device for Multiplex Screening of Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C and Syphilis in Sub-Saharan Africa","MAGICS IBCS","Inclusion Criteria:\n\n* Provide informed consent for participation in this study.\n* Patient sample must meet at least one of the criteria below:\n\n  1\\. Positive samples (serum or plasma) from individuals who meet at least one of the following conditions:\n* HIV-1 Ab positive\n* HIV-2 Ab positive\n* HCV-Ab positive\n* HBsAg positive\n* Positive for at least TPHA, with those positive for both TPHA and VDRL ideally included 2. Negative samples (serum or plasma) from individuals who meet at least one of the following conditions:\n* Blood donors\n* Hospitalized patients or individuals coming to the clinic\n* Vulnerable populations (such as: drug users, prison population, ...) 3. Negative samples (serum or plasma) containing potential interfering substances from individuals who meet at least one of the following conditions:\n* Being a pregnant woman\n* Infected with at least one of the following viruses or bacteria: hepatitis A virus (HAV), hepatitis E virus (HEV), tuberculosis (TB), gonorrhoea, chlamydia, influenza virus, Covid-19\n* Presenting any of the following criteria:\n\n  * High IgG levels\n  * High rheumatoid factor (\\>15 IU\u002FmL)\n  * High cholesterol levels (\\>0.24 md\u002FdL)\n  * High bilirubin levels (\\>0.25 mg\u002FmL)\n  * High triglyceride levels (\\>500 mg\u002FdL)\n  * Diagnosis of cancer\n\nExclusion Criteria:\n\n* Samples from patients below 18 years of age",true,{"count":58,"type":20},2950,"OBSERVATIONAL","Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from serum, plasma samples collected prospectively or retrospectively in Ivory Coast and Kenya.",[62,63,64,65,66,28],"Multiplex Testing of HIV, HBV, HCV and Syphilis","HIV","HBV","HCV","Syphilis",[68,63,64,65,66,69],"point of care test","multiplex testing","2026-01-30",{"date":72,"type":39},"2026-02-02",{"date":74,"type":39},"2025-07-29",{"date":76,"type":20},"2026-04",{"name":78,"class":79},"MagIA Diagnostics","INDUSTRY",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":101,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100581693","one-hour-troponin-using-a-high-sensitivity-point-of-care-assay-in-emergency-primary-care-100581693","NCT06853626","One-hoUr Troponin Using a High-sensitivity Point-Of-Care Assay in Emergency Primary Care","Improved Management of Acute Chest Pain in Emergency Primary Care. The OUT-POC Study (One-hoUr Troponin Using a High-sensitivity Point-Of-Care Assay in Emergency Primary Care)","OUT-POC","Inclusion Criteria:\n\n* Patients (18+ years) with non-traumatic acute chest pain presenting in emergency primary care\n* Troponin testing requested by the treating physician\n\nExclusion Criteria:\n\n* Acute STEMI (direct hospital referral required)\n* Haemodynamically unstable (direct hospital referral required)\n* Not able to provide written, informed consent (i.e., due to time restraints, language barriers, impaired cognitive function, or other reasons)",{"count":90,"type":20},2500,[23],"Acute chest pain is a prevalent medical emergency in primary emergency care settings. Triage of chest pain prior to hospital admission presents significant challenges due to the absence of sufficiently sensitive diagnostic tools. Clinical signs, symptoms, risk assessment scores, or a normal electrocardiogram (ECG) can reliably exclude acute myocardial infarction (MI). This diagnostic uncertainty has resulted in chest pain being the second most common cause for acute hospital referrals from Norwegian emergency primary care, even though chest pain is frequently non-cardiac in origin.\n\nIn acute MI events, cardiac troponins are released into the bloodstream from the damaged myocardium, where low values are used to exclude MI. Until recently, such testing has necessitated using high-sensitivity cardiac troponin (hs-cTn) assays, which have been limited to hospital laboratories. However, recent technological advancements in point-of-care (POC) testing allow access to whole-blood assays that meet high-sensitivity criteria.\n\nIn this upcoming project, the investigators will evaluate the implementation of a whole-blood POC assay (QuidelOrtho TriageTrue hs-cTnI) across six Norwegian emergency primary care clinics. The study plans to enrol 2,500 patients over a period of 1.5 years. The clinical performance of the novel strategy will be investigated, as well as its impact on healthcare utilization and hospital referrals compared to standard care. Additionally, the investigators will assess the prevalence of persistent chest pain and its effects on quality of life, alongside psychological stress and anxiety, through validated questionnaires.\n\nThis project aims to offer better and more comprehensive management of the large group of emergency primary care patients with acute chest pain, contributing to reduced hospital referrals, improved quality of life, and more sustainable use of healthcare services.",[94,95,96,97,98,28,99,100],"Acute Myocardial Infarction (AMI)","Chest Pain","Acute Coronary Syndromes (ACS)","Non-cardiac Chest Pain","Troponin","Out-of-hours Medical Care","Primary Care",[102,103,104,105,106,107,108,109,110,111,112,87,113],"TriageTrue","POC","hs-cTnI","0\u002F1-hour algorithm","troponin","chest pain","primary care","OOH","out-of-hours","acute myocardial infarction","point-of-care","QuidelOrtho","2025-12-09",{"date":116,"type":39},"2025-12-10",{"date":118,"type":39},"2025-06-27",{"date":120,"type":20},"2029-12-31",{"name":122,"class":46},"University of Oslo",6,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":59,"phases":4,"briefSummary":134,"conditions":135,"keywords":143,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":80},"100573775","the-impact-of-de-implementing-urine-dipsticks-for-diagnosis-of-utis-in-hospitals-100573775","NCT06750666","The Impact of De-implementing Urine Dipsticks for Diagnosis of UTIs in Hospitals","The Impact of De-implementing Urine Dipsticks for Diagnosis of Urinary Tract Infections in the North Denmark Region: An Interrupted Time-series Analysis","Inclusion Criteria:\n\n* All patients admitted to emergency rooms (≥18 years) from 2019 and forward.\n\nExclusion Criteria:\n\n* Patients directly admitted to an inpatient unit without first visiting an emergency room are excluded from the study.\n* For the primary analysis, only the first admission will be included; subsequent admissions will be excluded.",{"count":132,"type":20},480000,"30 Days","The goal of this interrupted time-series analysis is to evaluate the impact of the de-implementation of urine dipsticks as a diagnostic tool for urinary tract infections (UTIs) in hospitalized patients in the North Denmark Region. The main question it aims to answer is:\n\nHow does de-implementation of urine dipsticks affect the diagnosis and management of UTIs and related disorders?\n\nSpecifically, does it change the following parameters:\n\n* Number and severity of UTI infections (lower and upper UTI, non-severe and severe)\n* Antibiotic prescription (overall, antibiotic classes, administration routes, duration, dosages)\n* Number of urine cultures and number of positive urine cultures\n* Risks of admission to intensive care units and 30-day mortality\n* Risk of drug toxicity\n* Length of hospital stay\n* Risk of admission to intensive care unit\n* 30-day risk of readmission after discharge\n* 6-month risks of Clostridioides difficile enterocolitis and de novo antimicrobial resistance in cultures obtained during routine clinical care.\n\nResearchers hypothesize that de-implementing urine dipsticks will lead to a reduced frequency of diagnosed cystitis, reduced antibiotic use, and fewer urine cultures without negatively affecting patient mortality or readmission risk.\n\nResearchers will compare the outcomes before and after the discontinuation of urine dipsticks across hospitals in the North Denmark Region. Furthermore, results will be compared to another Danish administrative healthcare region where dipsticks are still in use as well as urine culture data from the primary sector in the North Denmark Region.\n\nSince this is a registry-based observational study utilizing data from the electronic patient record system in the North Denmark Region, no direct contact will be made with participants.",[136,137,138,139,140,141,142],"Urinary Tract Infections","Diagnostic Techniques and Procedures","Point-of-Care Testing","Anti-Bacterial Agents","Registry","Clinical Decision-making","Urinalysis",[144,136,145,146,147,148],"Urine Dipstick De-implementation","Hospital","Registry-Based Study","Clinical Impact","urine dipsticks","NOT_YET_RECRUITING","2025-09-30",{"date":152,"type":39},"2025-10-01",{"date":154,"type":20},"2025-12",{"date":156,"type":20},"2026-12",{"name":158,"class":46},"Jacob Bodilsen",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":47},"100582305","effect-of-point-of-care-analysis-of-ultrasensitive-troponin-i-on-length-of-hospital-stay-in-patients-with-cardiac-chest-pain-poc-troponina-100582305","NCT06861582","Effect of Point-of-care Analysis of Ultrasensitive Troponin I on Length of Hospital Stay in Patients With Cardiac Chest Pain (POC Troponina)","Effect of Point-of-care Analysis of Ultrasensitive Troponin I on Length of Hospital Stay in Patients With Cardiac Chest Pain: a Randomized Study (POC Troponina)","POC Troponina","Inclusion Criteria:\n\n* Patients aged ≥ 18 years.\n* Patients arriving in the emergency room with symptoms suggestive of ACS, with onset of pain between 3 and 12 hours after arrival, in whom serial troponin dosing is planned for investigation.\n* Signature of the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Patients presenting with ACS with ST-segment elevation on the 12-lead ECG on arrival at hospital.\n* Patients with conditions that interfere with the interpretation of troponin dosage (chronic renal failure, cancer, chronic lung diseases).\n* Pregnant or breastfeeding patients.\n* Patients already included in other clinical research protocols.",{"count":168,"type":20},200,[23],"This clinical study aims to compare two different methods for measuring high-sensitivity troponin I, a key biomarker used to diagnose heart attacks.\n\nThe primary research question is: Does the use of the Atellica VTLi kit from Siemens for high-sensitivity troponin I (hs-cTnI) testing at the point of care (POC) significantly reduce the average time from admission to hospital discharge compared to the conventional laboratory methodology using the Alinity i kit from ABBOTT?\n\nParticipant will:\n\n* Patients aged ≥ 18 years.\n* Patients arriving in the emergency room with symptoms suggestive of ACS, with onset of pain between 3 and 12 hours after arrival, in whom serial troponin dosing is planned for investigation.\n* Signature of the Informed Consent Form (ICF).\n\nResearchers will analyze whether the point-of-care testing method helps speed up the hospital discharge process compared to the standard laboratory approach. They will also compare the accuracy of the test results, the time taken for clinical decisions, and the overall cost-effectiveness of the two methods.",[96,172,138],"Troponin I",[174,175,172,138,176,177,178,179,180],"Acute Coronary Syndrome","Non-ST Elevation Myocardial Infarction","Biomarkers","Emergency Service, Hospital","Myocardial Ischemia","Cardiovascular Diseases","Hospital Length of Stay","2025-04-07",{"date":183,"type":39},"2025-04-08",{"date":185,"type":39},"2025-03-10",{"date":187,"type":20},"2026-03",{"name":189,"class":46},"University of Sao Paulo"]